Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
暂无分享,去创建一个
M. Silverberg | D. Rubin | G. Michalopoulos | U. Kopylov | U. Navaneethan | B. Bressler | G. Mantzaris | A. Yarur | S. Michopoulos | D. Demuth | J. Siffledeen | P. Karatzas | K. Soufleris | Andrew Singh | D. Stein | M. Bassel | E. Bellaguarda | A. Gatopoulou | Chris Fourment
[1] B. Sands,et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. , 2019, The New England journal of medicine.
[2] D. Latrémouille-Viau,et al. Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease , 2019, Crohn's & Colitis 360.
[3] B. Feagan,et al. Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis , 2019, Drug Safety.
[4] M. Ferrante,et al. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. , 2018, Inflammatory bowel diseases.
[5] T. Hardin,et al. Failure of Vedolizumab as First-Line Biologic Does Not Decrease Response Rates of Second-Line Therapy , 2018, American Journal of Gastroenterology.
[6] M. Stott-Miller,et al. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease. , 2018, Clinical therapeutics.
[7] Siddharth Singh,et al. Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium , 2018, The American Journal of Gastroenterology.
[8] Siddharth Singh,et al. Sa1723 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Crohn's Disease: A Multicenter Consortium Propensity Score-Matched Analysis , 2018 .
[9] W. Reinisch,et al. Tu2018 - Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease , 2018 .
[10] J. Ludvigsson,et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) , 2017, Scandinavian journal of gastroenterology.
[11] S. Vermeire,et al. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] T. Wyant,et al. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. , 2016, Journal of Crohn's & colitis.
[13] P. Rutgeerts,et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.
[14] S. Dalal,et al. What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. , 2015, Gastroenterology & hepatology.
[15] A. Ford,et al. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials , 2013, The American Journal of Gastroenterology.
[16] C. Porter,et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease , 2011, Inflammatory bowel diseases.
[17] R. Xavier,et al. Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.
[18] J. Robins,et al. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.
[19] B. Sands,et al. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy , 2017, Inflammatory bowel diseases.
[20] G. Porro,et al. Biologic Therapy for Inflammatory Bowel Disease , 2012, Drugs.